Literature DB >> 28663670

The Plasma and Serum Metabotyping of Hepatocellular Carcinoma in a Nigerian and Egyptian Cohort using Proton Nuclear Magnetic Resonance Spectroscopy.

Mohamed I F Shariff1, Jin Un Kim1, Nimzing G Ladep1, Asmaa I Gomaa2, Mary M E Crossey1,3, Edith Okeke4, Edmund Banwat4, Imam Waked2, I Jane Cox5, Roger Williams5, Elaine Holmes3, Simon D Taylor-Robinson1.   

Abstract

BACKGROUND/AIMS: Previous studies have observed disturbances in the 1H nuclear magnetic resonance (NMR) blood spectral profiles in malignancy. No study has metabotyped serum or plasma of hepatocellular carcinoma (HCC) patients from two diverse populations. We aimed to delineate the HCC patient metabotype from Nigeria (mostly hepatitis B virus infected) and Egypt (mostly hepatitis C virus infected) to explore lipid and energy metabolite alterations that may be independent of disease aetiology, diet and environment.
METHODS: Patients with HCC (53) and cirrhosis (26) and healthy volunteers (19) were recruited from Nigeria and Egypt. Participants provided serum or plasma samples, which were analysed using 600 MHz 1H NMR spectroscopy with nuclear Overhauser enhancement spectroscopy pulse sequences. Median group spectra comparison and multivariate analysis were performed to identify regions of difference.
RESULTS: Significant differences between HCC patients and healthy volunteers were detected in levels of low density lipoprotein (P = 0.002), very low density lipoprotein (P < 0.001) and lactate (P = 0.03). N-acetylglycoproteins levels in HCC patients were significantly different from both healthy controls and cirrhosis patients (P < 0.001 and 0.001).
CONCLUSION: Metabotype differences were present, pointing to disturbed lipid metabolism and a switch from glycolysis to alternative energy metabolites with malignancy, which supports the Warburg hypothesis of tumour metabolism.

Entities:  

Keywords:  1-D, One-dimensional; 1H NMR, proton nuclear magnetic resonance; AFP, α-fetoprotein; ALP, Alkaline phosphatase; ALT, Alanine transaminase; CT, Computed Tomography; EDTA, Ethylenediaminetetraacetic acid; ELISA, Enzyme-linked immunosorbent assay; Egypt; FID, Free induction decays; HBV, Hepatitis B virus; HBsAg, Hepatitis B surface antigen; HCC, Hepatocellular carcinoma; HCV, Hepatitis C virus; IDL, Intermediate density lipoprotein; IQR, Interquartile ranges; JUTH, Jos University Teaching Hospital; LDL, Low density lipoprotein; MRI, Magnetic resonance imaging; NOESY, Nuclear Overhauser enhancement spectroscopy; Nigeria; PC, Principal component; PCA, Principal components analysis; PLS-DA, Partial least squared discriminant analysis; PPARα, Peroxisome proliferator-activated receptor α; RD, Relaxation delay; US, Ultrasonography; VLDL, Very low density lipoprotein; WHO, World Health Organisation; hepatocellular carcinoma; ppm, Parts per million; proton nuclear magnetic resonance spectroscopy; serum metabotype; tm, Mixing time

Year:  2017        PMID: 28663670      PMCID: PMC5478965          DOI: 10.1016/j.jceh.2017.03.007

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  46 in total

1.  Analytical reproducibility in (1)H NMR-based metabonomic urinalysis.

Authors:  Hector C Keun; Timothy M D Ebbels; Henrik Antti; Mary E Bollard; Olaf Beckonert; Götz Schlotterbeck; Hans Senn; Urs Niederhauser; Elaine Holmes; John C Lindon; Jeremy K Nicholson
Journal:  Chem Res Toxicol       Date:  2002-11       Impact factor: 3.739

2.  Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study.

Authors:  Mohamed I F Shariff; Asmaa I Gomaa; I Jane Cox; Madhvi Patel; Horace R T Williams; Mary M E Crossey; Andrew V Thillainayagam; Howard C Thomas; Imam Waked; Shahid A Khan; Simon D Taylor-Robinson
Journal:  J Proteome Res       Date:  2011-03-09       Impact factor: 4.466

3.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

Review 4.  Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes.

Authors:  L Laffel
Journal:  Diabetes Metab Res Rev       Date:  1999 Nov-Dec       Impact factor: 4.876

5.  The low positive rate of serum alpha-fetoprotein levels in hepatitis C virus antibody-positive patients with hepatocellular carcinoma.

Authors:  J Furui; M Furukawa; T Kanematsu
Journal:  Hepatogastroenterology       Date:  1995 Sep-Oct

6.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

Review 7.  The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans.

Authors:  Ashish Shah; Daniel J Rader; John S Millar
Journal:  Atherosclerosis       Date:  2009-12-14       Impact factor: 5.162

Review 8.  Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond.

Authors:  Vadivel Ganapathy; Muthusamy Thangaraju; Puttur D Prasad
Journal:  Pharmacol Ther       Date:  2008-11-01       Impact factor: 12.310

9.  Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma.

Authors:  Elisa Wurmbach; Ying-bei Chen; Greg Khitrov; Weijia Zhang; Sasan Roayaie; Myron Schwartz; Isabel Fiel; Swan Thung; Vincenzo Mazzaferro; Jordi Bruix; Erwin Bottinger; Scott Friedman; Samuel Waxman; Josep M Llovet
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

10.  HMDB: the Human Metabolome Database.

Authors:  David S Wishart; Dan Tzur; Craig Knox; Roman Eisner; An Chi Guo; Nelson Young; Dean Cheng; Kevin Jewell; David Arndt; Summit Sawhney; Chris Fung; Lisa Nikolai; Mike Lewis; Marie-Aude Coutouly; Ian Forsythe; Peter Tang; Savita Shrivastava; Kevin Jeroncic; Paul Stothard; Godwin Amegbey; David Block; David D Hau; James Wagner; Jessica Miniaci; Melisa Clements; Mulu Gebremedhin; Natalie Guo; Ying Zhang; Gavin E Duggan; Glen D Macinnis; Alim M Weljie; Reza Dowlatabadi; Fiona Bamforth; Derrick Clive; Russ Greiner; Liang Li; Tom Marrie; Brian D Sykes; Hans J Vogel; Lori Querengesser
Journal:  Nucleic Acids Res       Date:  2007-01       Impact factor: 16.971

View more
  2 in total

1.  Metabolomics technology and bioinformatics for precision medicine.

Authors:  Rajeev K Azad; Vladimir Shulaev
Journal:  Brief Bioinform       Date:  2019-11-27       Impact factor: 11.622

2.  Plasma lipids, tumor parameters and survival in HCC patients with HBV and HCV.

Authors:  H Akkiz; B I Carr; V Guerra; R Donghia; K Yalçın; U Karaoğullarından; E Altıntaş; A Özakyol; H Şimşek; H Y Balaban; A Balkan; A Uyanıkoğlu; N Ekin; A Delik
Journal:  J Transl Sci       Date:  2020-09-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.